| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
65,650,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vor Biopharma is a cell therapy company. Co.'s primary focus is on patients suffering from acute myeloid leukemia (AML). Co. develops treatments for patients suffering from hematological malignancies. Co. is developing its primary eHSC product candidate, VOR33, which it has potential to transform the treatment for AML and other blood cancers. CD33 is a clinically validated target for AML. Co. has initiated VBP101, a Phase 1/2a clinical trial in patients with CD33-positive AML who are at high risk of relapse. Co. is also developing its Treatment System comprising the VOR33-CLL1 multiplex-edited eHSC therapy and the VCAR33-CLL1 multi-specific CAR-T therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jorgensen Nathan D. |
CHIEF FINANCIAL OFFICER |
• – – |
2024-03-01 |
4 |
D |
$2.27 |
$14,324 |
D/D |
(6,310) |
191,154 |
|
- |
|
| Ang Robert |
PRESIDENT AND CEO |
• • – |
2024-03-01 |
4 |
D |
$2.27 |
$28,731 |
D/D |
(12,657) |
815,480 |
|
- |
|
| Chakraborty Tirtha |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-03-01 |
4 |
D |
$2.27 |
$12,658 |
D/D |
(5,576) |
181,093 |
|
- |
|
| Jorgensen Nathan D. |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-06 |
4 |
D |
$2.32 |
$2,285 |
D/D |
(985) |
197,464 |
|
- |
|
| Attar Eyal C. |
CHIEF MEDICAL OFFICER |
• – – |
2024-02-06 |
4 |
D |
$2.32 |
$2,738 |
D/D |
(1,180) |
112,853 |
|
- |
|
| Ang Robert |
PRESIDENT AND CEO |
• • – |
2024-02-06 |
4 |
D |
$2.32 |
$6,468 |
D/D |
(2,788) |
828,137 |
|
- |
|
| Chakraborty Tirtha |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-02-06 |
4 |
D |
$2.32 |
$2,397 |
D/D |
(1,033) |
186,669 |
|
- |
|
| Attar Eyal C. |
CHIEF MEDICAL OFFICER |
• – – |
2024-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
114,033 |
|
- |
|
| Jorgensen Nathan D. |
CHIEF FINANCIAL OFFICER |
• – – |
2024-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
198,449 |
|
- |
|
| Ang Robert |
PRESIDENT AND CEO |
• • – |
2024-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
830,925 |
|
- |
|
| Chakraborty Tirtha |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
53,750 |
187,702 |
|
- |
|
| Jorgensen Nathan D. |
Chief Financial Officer |
• – – |
2023-11-06 |
4 |
D |
$1.82 |
$1,518 |
D/D |
(834) |
145,647 |
|
- |
|
| Attar Eyal C. |
Chief Medical Officer |
• – – |
2023-11-06 |
4 |
D |
$1.82 |
$1,818 |
D/D |
(999) |
51,533 |
|
- |
|
| Chakraborty Tirtha |
Chief Scientific Officer |
• – – |
2023-11-06 |
4 |
D |
$1.82 |
$1,594 |
D/D |
(876) |
133,952 |
|
- |
|
| Ang Robert |
President and CEO |
• • – |
2023-11-06 |
4 |
D |
$1.82 |
$4,297 |
D/D |
(2,361) |
680,925 |
|
- |
|
| Ang Robert |
President and CEO |
• • – |
2023-09-01 |
4 |
D |
$2.67 |
$33,794 |
D/D |
(12,657) |
683,286 |
|
- |
|
| Jorgensen Nathan D. |
Chief Financial Officer |
• – – |
2023-09-01 |
4 |
D |
$2.67 |
$16,848 |
D/D |
(6,310) |
146,481 |
|
- |
|
| Chakraborty Tirtha |
Chief Scientific Officer |
• – – |
2023-09-01 |
4 |
D |
$2.67 |
$14,888 |
D/D |
(5,576) |
134,828 |
|
- |
|
| Ang Robert |
President and CEO |
• • – |
2023-08-07 |
4 |
D |
$2.67 |
$6,304 |
D/D |
(2,361) |
695,943 |
|
- |
|
| Chakraborty Tirtha |
Chief Scientific Officer |
• – – |
2023-08-07 |
4 |
D |
$2.67 |
$2,336 |
D/D |
(875) |
140,404 |
|
- |
|
| Attar Eyal C. |
Chief Medical Officer |
• – – |
2023-08-07 |
4 |
D |
$2.67 |
$2,667 |
D/D |
(999) |
52,532 |
|
- |
|
| Jorgensen Nathan D. |
Chief Financial Officer |
• – – |
2023-08-07 |
4 |
D |
$2.67 |
$2,227 |
D/D |
(834) |
152,791 |
|
- |
|
| Jorgensen Nathan D. |
Chief Financial Officer |
• – – |
2023-05-08 |
4 |
D |
$4.14 |
$3,453 |
D/D |
(834) |
153,625 |
|
- |
|
| Attar Eyal C. |
Chief Medical Officer |
• – – |
2023-05-08 |
4 |
D |
$4.14 |
$4,012 |
D/D |
(969) |
53,531 |
|
- |
|
| Ang Robert |
President and CEO |
• • – |
2023-05-08 |
4 |
D |
$4.14 |
$9,775 |
D/D |
(2,361) |
698,304 |
|
- |
|
53 Records found
|
|
Page 1 of 3 |
|
|
